Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143385

Published: 2020

Journal Articles

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Grace Hwang, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, BCOP, Anil Aktas-Samur, PhD, Jacob P. Laubach, MD, Aric D. Parnes, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140175

Published: 2020

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2019) 134 (Supplement_1): 580.

https://doi.org/10.1182/blood-2019-128519

Published: 2019

Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2018) 132 (Supplement 1): 804.

https://doi.org/10.1182/blood-2018-99-117871

Published: 2018

Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD

Blood (2018) 132 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2018-99-111361

Published: 2018

Journal Articles

Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs

Houry Leblebjian, PharmD, Joanna Hamilton, MA, MS, Sydney Smith, PharmD, Jacob Laubach, MD, Nancy Berliner, MD, Aric Parnes, MD

Blood (2018) 132 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2018-99-115436

Published: 2018

Journal Articles

Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule

Elaine Xiang, PharmD, Hillary Prescott, PharmD, Jacob Laubach, MD, Paul Richardson, Kaitlen Reyes, NP, Irene M. Ghobrial, MD, Houry Leblebjian, PharmD

Blood (2018) 132 (Supplement 1): 2024.

https://doi.org/10.1182/blood-2018-99-111191

Published: 2018

Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Blood (2017) 130 (Supplement 1): 5397.

https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397

Published: 2017

Journal Articles

Direct Oral Anticoagulants in Anti-Phospholipid Syndrome

Houry Leblebjian, PharmD, Aric Parnes, MD

Blood (2017) 130 (Supplement 1): 2145.

https://doi.org/10.1182/blood.V130.Suppl_1.2145.2145

Published: 2017

Journal Articles

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Blood (2017) 130 (Supplement 1): 392.

https://doi.org/10.1182/blood.V130.Suppl_1.392.392

Published: 2017

Journal Articles

Adverse Events in Patients with Cancer Treated with Direct Oral Anticoagulants and Cancer Therapy

Huong L Truong, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, Christy Harris, PharmD, Jean M. Connors, BA,MD

Blood (2017) 130 (Supplement 1): 2396.

https://doi.org/10.1182/blood.V130.Suppl_1.2396.2396

Published: 2017

Journal Articles

Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma

Blood (2016) 128 (22): 197.

https://doi.org/10.1182/blood.V128.22.197.197

Published: 2016

Journal Articles

Single-Center Experience with Romiplostim for Management of Chemotherapy-Induced Thrombocytopenia (CIT)

Jennifer Miao, Pharm.D., Houry Leblebjian, PharmD, Bridget Fowler-Scullion, Pharm.D., BCOP, Aric Parnes, MD

Blood (2016) 128 (22): 530.

https://doi.org/10.1182/blood.V128.22.530.530

Published: 2016

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Houry Leblebjian, PharmD, BCOP, Wanling Xie, MS, Paul G. Richardson, MD, Irene M. Ghobrial, MD, Christy Harris, PharmD, BCPS, BCOP, Robert L Schlossman, MD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Sylvia Bartel, R.Ph., M.H.P., Kenneth C. Anderson, MD, Edie A. Weller, PhD, Jacob P. Laubach, MD

Blood (2013) 122 (21): 1977.

https://doi.org/10.1182/blood.V122.21.1977.1977

Published: 2013

NARROW

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs

Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Direct Oral Anticoagulants in Anti-Phospholipid Syndrome

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Adverse Events in Patients with Cancer Treated with Direct Oral Anticoagulants and Cancer Therapy

Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma

Single-Center Experience with Romiplostim for Management of Chemotherapy-Induced Thrombocytopenia (CIT)

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only